Washington Report

Nov 01, 2005
Pharmaceutical Executive
The circumstances of Crawford's departure may complicate the process of securing a permanent FDA leader. Congress and HHS are investigating whether his confirmation process failed to uncover important facts.
Oct 01, 2005
Pharmaceutical Executive
Many still regard FDA's approach as costly and unnecessary. But the prospect of qualifying for purchase by PEPFAR is attracting applicants. The policy has helped bring news AIDS treatments to market.
Sep 01, 2005
Pharmaceutical Executive
FDA could lose 251 employees under the administration's proposed 2006 budget. The agency will try to do more with less through risk-management practices, but important tasks will fall by the wayside.
Aug 01, 2005
Pharmaceutical Executive
Integra v. Merck KGaA supports research by large pharmaceutical companies, but it also opens the door to greater use of compounded materials by all parties. Congress may have to clarify its scope.
Jul 01, 2005
Pharmaceutical Executive
Pharma companies believe that they can compete in an e-prescribing environment if information systems permit full disclosure and allow doctors to create bookmarks that link easily to information they want.
Jun 01, 2005
Pharmaceutical Executive
CMS envisions studies to show which drugs keep patients out of hospitals or how certain treatments can reduce side effects. Such analysis would support decisions on best practices in using medications.
May 01, 2005
Pharmaceutical Executive
Just a decade ago, FDA was accused of dragging its feet on new drug applications. Now, supposedly, the agency is moving so fast that it's letting unsafe, insufficiently tested products into the marketplace.
Apr 01, 2005
Pharmaceutical Executive
Reformers want to give FDA more clout, but agency officials say internal changes will help fix drug safety problems.
Mar 01, 2005
Pharmaceutical Executive
Should policy makers expect 90 percent of seniors to enroll in PDPs, or will 75 percent be enough? Will the program have to keep costs down to $400 billion a year, or will spending be linked to savings elsewhere?
Feb 01, 2005
Pharmaceutical Executive
One response to today's safety concerns is particularly alarming: The research community has become skittish about conducting clinical studies involving pain medications and other high-risk treatments.
native1_300x100
lorem ipsum